MediMabBio is a ground-breaking biotherapeutic company focusing on the generation of novel immunotherapies for the treatment of cancer. Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors. The company has developed a pipeline of highly promising novel drugs that aims to overcome the current limitations of cancer immunotherapy. For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.
MediMabBio 외부 링크
#721, 54, Changeop-ro, Sujeong-gu
KR Gyeonggi-do Seongnam-si 13449
MediMabBio님이 퍼감
We're thrilled to announce that #Celltrion has selected #MediMabBio as one of the four biotech startups for its Open Innovation Program. This initiative, in partnership with #SeoulBiohub, is part of Celltrion’s strategy to drive innovation and progress in the biotech industry. Recognized for our innovative potential, MediMabBio is set to greatly benefit from Celltrion’s network, resources, and expertise.
MediMabBio is pleased to announce that we will be giving a poster presentation at EACR2024. 📅 Event: EACR2024 (10-13 June, Rotterdam) 📜 Poster Presentation Title: "Development of a Novel Anti-TIGIT IL-15 Fusion Antibody for Enhanced Anti-Tumour Therapy" (Presented on 11 June 2024) Our team will present insights into our groundbreaking work on the anti-TIGIT IL-15 fusion antibody, aimed at revolutionizing cancer treatment. We look forward to engaging with fellow researchers, industry experts, and partners at EACR2024. See you there! #MediMabBio #EACR2024 #Biotech #Immunotherapy
MediMabBio is thrilled to announce our participation in the BIO International Convention 2024! Our team is looking forward to exploring new opportunities and potential partnerships. If you're interested in discussing collaboration opportunities, please send us a meeting request. #BIO2024 #MediMabBio
MediMabBio님이 퍼감
MediMabBio Signs MoU with PDC*line Pharma to Collaborate on Cancer Immunotherapy We are excited to announce a new memorandum of understanding (MOU) with PDC*line Pharma. This collaboration is aimed to explore the synergy between our MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionize cancer treatment. Together, our promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, we aim to boost the efficacy of our therapies and explore innovative treatment strategies. Stay connected for updates on our collaborative efforts to advance groundbreaking cancer treatments. #CancerResearch #Immunotherapy #Biotech #Partnership #MediMabBio #PDClinePharma
MediMabBio Signs MoU with PDC*line Pharma to Collaborate on Cancer Immunotherapy We are excited to announce a new memorandum of understanding (MOU) with PDC*line Pharma. This collaboration is aimed to explore the synergy between our MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionize cancer treatment. Together, our promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, we aim to boost the efficacy of our therapies and explore innovative treatment strategies. Stay connected for updates on our collaborative efforts to advance groundbreaking cancer treatments. #CancerResearch #Immunotherapy #Biotech #Partnership #MediMabBio #PDClinePharma
MediMabBio is ready for BIO-Europe Spring 2024! Seeking partnerships in biotech. Reach out to collaborate. #BIOEuropeSpring2024 #MediMabBio #innovationinhealthcare
Thrilled to welcome Eun-Hyuk Chang as our new Chief Strategy Officer at MediMabBio! With his extensive experience in R&BD and strategic planning within the industry, we look forward to his contributions in enhancing our drug development and strategic endeavors.
MediMabBio님이 퍼감
We're thrilled to announce that #Celltrion has selected #MediMabBio as one of the four biotech startups for its Open Innovation Program. This initiative, in partnership with #SeoulBiohub, is part of Celltrion’s strategy to drive innovation and progress in the biotech industry. Recognized for our innovative potential, MediMabBio is set to greatly benefit from Celltrion’s network, resources, and expertise.
We're thrilled to announce that #Celltrion has selected #MediMabBio as one of the four biotech startups for its Open Innovation Program. This initiative, in partnership with #SeoulBiohub, is part of Celltrion’s strategy to drive innovation and progress in the biotech industry. Recognized for our innovative potential, MediMabBio is set to greatly benefit from Celltrion’s network, resources, and expertise.
MediMabBio님이 퍼감
MediMabBio is set to participate in BIO Partnering @JPM Week. We welcome the opportunity to arrange an in-person meeting in San Francisco or a virtual discussion. We look forward to connecting with you.